Starpharma Holdings Limited is a world leader in dendrimer technology for medical applications. This innovative Australian biopharmaceutical company focuses on developing and commercializing novel therapeutic products to address significant global healthcare needs. Starpharma's portfolio includes a range of products, partnerships, and intellectual property.

Their proprietary technology is based on dendrimers, precise nanoscale molecules with unique properties such as size, structure, and water solubility. These properties make dendrimers advantageous in medical and pharmaceutical applications. Starpharma utilizes dendrimer technology to develop novel therapeutics and enhance the performance of existing pharmaceuticals.

Their portfolio features multiple clinical stage oncology products that utilize their Dendrimer Enhanced Product (DEP®) drug delivery technology. They also have marketed products like VIRALEZE™ and VivaGel® BV, which leverage SPL7013, a proprietary dendrimer with antimicrobial properties. Starpharma's DEP® drug delivery platform enhances the effectiveness of therapies and reduces drug-related toxicities through controlled and specified drug delivery.

Additionally, Starpharma has several DEP® partnerships with renowned biopharmaceutical companies, offering broad applicability and potential future milestones and royalties. Notably, VIRALEZE™ is registered in over 35 countries, while VivaGel® BV is registered in over 50 countries. Please note that VIRALEZE™ is not approved for use or supply in Australia